Chronic Lymphocytic Leukemia (CLL) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Chronic Lymphocytic Leukemia (CLL) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Chronic Lymphocytic Leukemia (CLL) - Drugs In Development, 2022, provides an overview of the Chronic Lymphocytic Leukemia (CLL) (Oncology) pipeline landscape.

Chronic lymphocytic leukemia (CLL) is a type of cancer that starts from white blood cells (called lymphocytes) in the bone marrow. It then invades the blood. Symptoms usually develop slowly. Symptoms of CLL include abnormal bruising (if platelets are low), fever, infections that keep coming back (recur), loss of appetite or becoming full too quickly (early satiety) and weight loss. Treatment options include surgery, radiation therapy, chemotherapy or a combination of methods.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Chronic Lymphocytic Leukemia (CLL) - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Chronic Lymphocytic Leukemia (CLL) (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Chronic Lymphocytic Leukemia (CLL) (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Chronic Lymphocytic Leukemia (CLL) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 5, 4, 6, 75, 111, 9, 16, 72, 11 and 2 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 10, 19, 15 and 6 molecules, respectively.

Chronic Lymphocytic Leukemia (CLL) (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Chronic Lymphocytic Leukemia (CLL) (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Chronic Lymphocytic Leukemia (CLL) (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Chronic Lymphocytic Leukemia (CLL) (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Chronic Lymphocytic Leukemia (CLL) (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Chronic Lymphocytic Leukemia (CLL) (Oncology)
Reasons to Buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Chronic Lymphocytic Leukemia (CLL) (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Chronic Lymphocytic Leukemia (CLL) (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.


Introduction
Global Markets Direct Report Coverage
Chronic Lymphocytic Leukemia (CLL) – Overview
Chronic Lymphocytic Leukemia (CLL) – Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Chronic Lymphocytic Leukemia (CLL) – Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Chronic Lymphocytic Leukemia (CLL) – Companies Involved in Therapeutics Development
AbbVie Inc
ABL Bio Inc
Acerta Pharma BV
Achelois Cell Therapy
Actinium Pharmaceuticals Inc
Actinobac Biomed Inc
ADC Therapeutics SA
Adlai Nortye Biopharma Co Ltd
Advenchen Laboratories LLC
AI Therapeutics Inc
Alaunos Therapeutics Inc
Alloplex Biotherapeutics Inc
Amgen Inc
Apotex Inc
Ardan Pharma
Ascenta Therapeutics Inc
Ascentage Pharma Group International
Astellas Pharma Inc
AstraZeneca Plc
Athenex Inc
Aucentra Therapeutics Pty Ltd
Autolus Therapeutics Plc
Avesthagen Ltd
AVM Biotechnology LLC
BAKX Therapeutics Inc
Bantam Pharmaceutical LLC
Bayer AG
BeiGene Ltd
Beijing Gaobo Biotechnology Co Ltd
Beijing GD Initiative Cell Therapy Technology Co Ltd
Beijing Jingda Biotechnology Co Ltd
Beijing Mabworks Biotech Co Ltd
Bio-Path Holdings Inc
Biocure Technology Inc
Biogen Inc
BioIntegrator
Biomea Fusion Inc
Bionomics Ltd
BioNTech SE
BioXpress Therapeutics SA
Boryung Pharmaceutical Co Ltd
Bristol-Myers Squibb Co
Carna Biosciences Inc
CARsgen Therapeutics Ltd
CasInvent Pharma AS
Catalent Inc
Catapult Therapeutics BV
Cellectar Biosciences Inc
Cellular Biomedicine Group Inc
Celularity Inc
Century Therapeutics Inc
Checkpoint Therapeutics Inc
Chengdu Brilliant Pharmaceutical Co Ltd
Chengdu Hyperway Pharmaceutical Co Ltd
Chengdu Jinrui Foundation Biotechnology Co Ltd
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Chimeric Therapeutics Ltd
Chongqing Precision Biotech Co Ltd
Clonz Biotech Pvt Ltd
CoImmune Inc
Conjupro Biotherapeutics Inc
CrystalGenomics Inc
CSPC Pharmaceutical Group Ltd
Curis Inc
Cyclacel Pharmaceuticals Inc
Cyteir Therapeutics Inc
Dren Bio Inc
Eli Lilly and Co
EntreChem SL
Eternity Bioscience Inc
Eureka Therapeutics Inc
Evopoint Bioscience Co Ltd
Excelmab Inc
Exelixis Inc
Exinda Therapeutics LLC
F. Hoffmann-La Roche Ltd
Fate Therapeutics Inc
Fochon Pharmaceutical Ltd
Galapagos NV
GeneaMed Ltd
Genentech USA Inc
GenFleet Therapeutics (Shanghai) Inc
Genmab AS
Genor BioPharma Co Ltd
Gilead Sciences Inc
GLG Pharma SA
Grid Therapeutics LLC
Grifols SA
Grupo Ferrer Internacional SA
GSK plc
GT Biopharma Inc
Guangdong East Sunshine Pharmaceutical Co Ltd
Guangzhou BeBetter Medicine Technology Co Ltd
Guangzhou Bio-gene Technology Co Ltd
Haisco Pharmaceutical Group Co Ltd
Hangzhou Hezheng Pharmaceutical Co Ltd
Hangzhou Minsheng Pharmaceutical Group Co Ltd
Hangzhou Sumgen Biotech Co Ltd
Hangzhou Zenshine Pharmaceuticals Co Ltd
Hebei Senlang Biotechnology Co Ltd
Heidelberg Pharma AG
Helocyte Biosciences Inc
HK inno.N Corp
Hutchison MediPharma Ltd
Hybrigenics SA
iBio Inc
IDP Discovery Pharma SL
IGM Biosciences Inc
Iksuda Therapeutics Ltd
Immatics NV
ImmuneOnco Biopharmaceuticals (Shanghai) Co Ltd
ImmuneTarget Inc
ImmunityBio Inc
Incyte Corp
Inflection Biosciences Ltd
InnoBation Bio
InnoCare Pharma Ltd
IO Biotech Inc
Iovance Biotherapeutics Inc
Jiangsu Maidu Drug Research and Development Co Ltd
Johnson & Johnson
Juventas Cell Therapy Ltd
Kancera AB
Kangpu Biopharmaceuticals Ltd
Kartos Therapeutics Inc
Karus Therapeutics Ltd
Karyopharm Therapeutics Inc
Kite Pharma Inc
Lanzhou Institute of Biological Products Co Ltd
LAVA Therapeutics NV
LegoChem Biosciences Inc
Light Chain Bioscience
LintonPharm Co Ltd
Loxo Oncology Inc
LTZ Therapeutics Inc
Mabion SA
ManysmarT Therapeutics Inc
MedPacto Inc
MEI Pharma Inc
MENTRIK Biotech LLC
Merck & Co Inc
Millennium Pharmaceuticals Inc
Miltenyi Biomedicine GmbH
Minghui Pharmaceutical (Shanghai) Co Ltd
MingSight Pharmaceuticals Inc
MiNK Therapeutics Inc
MorphoSys AG
Mustang Bio Inc
Nanjing Aimeifei Biomedical Technology Co Ltd
Nanjing Bioheng Biotech Co Ltd
Nanjing Iaso Biotherapeutics Co Ltd
Nanjing Sanhome Pharmaceutical Co Ltd
Newave Pharmaceutical Inc
Nichi-Iko Pharmaceutical Co Ltd
Nordic Nanovector ASA
NovalGen Ltd
Novartis AG
Nurix Therapeutics Inc
Octapharma AG
OncoTartis Inc
Oncternal Therapeutics
Ono Pharmaceutical Co Ltd
Orano Med LLC
PersonGen BioTherapeutics (Suzhou) Co Ltd
Pfizer Inc
Pharmapraxis
PIQUR Therapeutics AG
Plexxikon Inc
Precigen Inc
Precision Biosciences Inc
Qilu Pharmaceutical Co Ltd
Qilu Puget Sound Biotherapeutics Corp
Remd Biotherapeutics Inc
Repare Therapeutics Inc
Rhizen Pharmaceuticals SA
Sana Biotechnology Inc
Sanofi
Schrodinger Inc
Secura Bio Inc
SFA Therapeutics Inc
Shandong New Time Pharmaceutical Co Ltd
Shanghai Haiyan Pharmaceutical Technology Co Ltd
Shanghai Simnova Biotechnology Co Ltd
Shanghai YaKe Biotechnology Co Ltd
Shanghai Yingli Pharmaceutical Co Ltd
Shengke Pharmaceuticals (Jiangsu) Ltd
Shenzhen Targetrx Inc
Shouyao Holding Co Ltd
Sian Wuhan Medical Technology Co Ltd
Sino Biopharmaceutical Ltd
Sorrento Therapeutics Inc
SpecificiT Pharma Inc
Starton Therapeutics Inc
Supratek Pharma Inc
Suzhou Fundamenta Therapeutics Co Ltd
Suzhou JiSheng Pharmaceutical Co Ltd
Swedish Orphan Biovitrum AB
Systimmune Inc
Takeda Pharmaceutical Co Ltd
Targazyme Inc
TC BioPharm Ltd
Telios Pharma Inc
TG Therapeutics Inc
Tiannuojiancheng Pharma
TransThera Sciences (Nanjing) Inc
Ubix Therapeutics Inc
United BioPharma Inc
Vincerx Pharma Inc
Viridian Therapeutics Inc
Wuhan Bio-Raid Biotechnology Co Ltd
XEME BioPharma Inc
Xencor Inc
Xi'An Yufan Biotechnology Co Ltd
Zhejiang DTRM Biopharma LLC
Zhejiang Hisun Pharmaceutical Co Ltd
Zhejiang Longchuan Biomedical Technology Co Ltd
Zhejiang Teruisi Pharmaceutical Co Ltd
Zhengda Tianqing Pharmaceutical Group Co Ltd
Zibo Baiji Changsheng Pharmaceutical Co Ltd
Zylem Biosciences Inc
Chronic Lymphocytic Leukemia (CLL) – Drug Profiles
(DTRMWXHS-12 + everolimus + pomalidomide) – Drug Profile
(IO-103 + IO-120) – Drug Profile
4EGI-1 – Drug Profile
ABBV-319 – Drug Profile
ABBV-623 – Drug Profile
ABBV-992 – Drug Profile
abivertinib maleate – Drug Profile
ABL-102 – Drug Profile
ABL-203 – Drug Profile
acalabrutinib maleate – Drug Profile
ACP-319 – Drug Profile
ACY-738 – Drug Profile
AGENT-797 – Drug Profile
AL-58805 – Drug Profile
Alpha37 – Drug Profile
amdizalisib – Drug Profile
anakinra – Drug Profile
Anti-CD19/CD20/CD22 CAR T-cells – Drug Profile
anti-CD20 CAR-T cells – Drug Profile
anti-CD22 CAR-T cells – Drug Profile
APG-2575 – Drug Profile
apilimod mesylate – Drug Profile
ARDAN-0171 – Drug Profile
AS-1763 – Drug Profile
AT-101 – Drug Profile
atezolizumab – Drug Profile
AU-07 – Drug Profile
AUTO-1NG – Drug Profile
avadomide hydrochloride – Drug Profile
AZD-4573 – Drug Profile
B-9 – Drug Profile
BCNCP-01 – Drug Profile
BCP-402 – Drug Profile
belimumab – Drug Profile
bendamustine – Drug Profile
bendamustine hydrochloride – Drug Profile
BGB-10188 – Drug Profile
BGB-11417 – Drug Profile
BGB-16673 – Drug Profile
BI-09 – Drug Profile
bimiralisib – Drug Profile
BKX-001 – Drug Profile
blinatumomab – Drug Profile
BMF-219 – Drug Profile
BMS-986403 – Drug Profile
BNC-105 – Drug Profile
Boritinib – Drug Profile
BP-1002 – Drug Profile
BR-101801 – Drug Profile
brexucabtagene autoleucel – Drug Profile
BT-1053 – Drug Profile
buparlisib hydrochloride – Drug Profile
camonsertib – Drug Profile
CAP-100 – Drug Profile
CAR-NK-CD19 Cells – Drug Profile
CAR-T Cell – Drug Profile
CAR-T Cells to Treat Malignant B Neoplasms – Drug Profile
CAT-04106 – Drug Profile
CC-115 – Drug Profile
CC-99282 – Drug Profile
CCAR-066 – Drug Profile
CD19 CAR-T Cells – Drug Profile
CD20/CD22 Targeted CAR T-cell Therapy – Drug Profile
CD56 Enriched Donor Lymphocyte Infusion – Drug Profile
CD70 CAR T-cells – Drug Profile
CD79b CAR-T Therapy – Drug Profile
Cellular Immunotherapy for Hematological Malignancies – Drug Profile
Cellular Immunotherapy for Hematological Malignancy and Solid Tumor – Drug Profile
Cellular Immunotherapy for Multiple Myeloma and Chronic Lymphocytic Leukemia – Drug Profile
Cellular Immunotherapy for Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia – Drug Profile
Cellular Immunotherapy for Oncology – Drug Profile
Central Memory-Enriched T Cells – Drug Profile
CHM-0201 – Drug Profile
CM-355 – Drug Profile
CMN-005 – Drug Profile
CNCT-19 – Drug Profile
CNTY-102 – Drug Profile
cobomarsen – Drug Profile
copanlisib hydrochloride – Drug Profile
cosibelimab – Drug Profile
crenigacestat – Drug Profile
CSG-CD19 – Drug Profile
CT-1995 – Drug Profile
CTA-101 – Drug Profile
CTA-301 – Drug Profile
CTL-19 – Drug Profile
CTRD-06 – Drug Profile
CTX-177 – Drug Profile
CUDC-908 – Drug Profile
CX-1440 – Drug Profile
CYNK-001 – Drug Profile
CYT-0851 – Drug Profile
daratumumab – Drug Profile
dexamethasone sodium phosphate – Drug Profile
dezapelisib – Drug Profile
DF-07 – Drug Profile
DR-0201 – Drug Profile
Drug to Target ROR-1 and TOSO for Chronic Lymphocytic Leukemia – Drug Profile
DTRMWXHS-12 – Drug Profile
durvalumab – Drug Profile
duvelisib – Drug Profile
EC-7072 – Drug Profile
edralbrutinib – Drug Profile
EF-02 – Drug Profile
enitociclib – Drug Profile
enzalutamide – Drug Profile
epcoritamab – Drug Profile
ET-019002 – Drug Profile
ETH-155008 – Drug Profile
EX-103 – Drug Profile
EX-104 – Drug Profile
EX-301 – Drug Profile
FAB-114 – Drug Profile
fadraciclib – Drug Profile
favezelimab – Drug Profile
FCN-338 – Drug Profile
FCN-647 – Drug Profile
fenebrutinib – Drug Profile
FT-596 – Drug Profile
FT-819 – Drug Profile
Fully-Human Anti-CD19 Chimeric Antigen Receptor – Drug Profile
GB-261 – Drug Profile
GD-CLL – Drug Profile
gebasaxturev – Drug Profile
GEM-155/19CAR-T – Drug Profile
GEN-3009 – Drug Profile
Gene Modified Cell Therapy to Target CD19 for Blood Cancer – Drug Profile
Gene Therapy for Hematological and Solid Tumors – Drug Profile
Gene Therapy for Oncology – Drug Profile
Gene Therapy to Target CD19 and CD20 for Blood Cancers – Drug Profile
Gene Therapy to Target CD19 and CD20 for Oncology – Drug Profile
Gene Therapy to Target CD19 and CD20 for Oncology and Neuromyelitis Optica (Devic’s Syndrome) – Drug Profile
Gene Therapy to Target CD19 and CD22 for Acute Lymphocytic Leukemia and Non-Hodgkin Lymphoma – Drug Profile
Gene Therapy to Target CD19 and CD22 for Oncology – Drug Profile
Gene Therapy to Target CD19 and IL-18R for Chronic Lymphocytic Leukemia (CLL) and Non-Hodgkin Lymphoma – Drug Profile
Gene Therapy to Target CD19 for Acute Lymphoblastic Leukemia – Drug Profile
Gene Therapy to Target CD19 for Acute Lymphocytic Leukemia – Drug Profile
Gene Therapy to Target CD19 for B-cell Malignancies – Drug Profile
Gene Therapy to Target CD19 for Blood Cancer – Drug Profile
Gene Therapy to Target CD19 for Chronic Lymphocytic Leukemia – Drug Profile
Gene Therapy to Target CD19 for Leukemia or Lymphoma – Drug Profile
Gene Therapy to Target CD19 for Oncology – Drug Profile
Gene Therapy to Target CD22 for Chronic Lymphocytic Leukemia, Diffuse Large B-Cell Lymphoma and Follicular Lymphoma – Drug Profile
Gene Therapy to Target CD22 for Oncology – Drug Profile
Gene therapy To Target CD37 for Hematologic Malignancies – Drug Profile
Gene Therapy to Target CD7 for Oncology – Drug Profile
Gene Therapy to Target Ig Kappa and CD28 for Oncology – Drug Profile
Gene Therapy to Target MS4A1 for Chronic Lymphocytic Leukemia, Refractory and Relapsed Diffuse Large B-cell Lymphoma – Drug Profile
Gene Therapy to Target Toso for Chronic Lymphocytic Leukemia – Drug Profile
Gene-Modified Cell Therapy to Target CD19, CD20 and CD22 for Relapsed and Refractory B-cell Malignancies – Drug Profile
GFH-009 – Drug Profile
GNC-035 – Drug Profile
GT-103 – Drug Profile
GTB-7550 – Drug Profile
HBW-3220 – Drug Profile
HBX-19818 – Drug Profile
HDP-101 – Drug Profile
HEC-89736 – Drug Profile
HMPL-760 – Drug Profile
HSK-29116 – Drug Profile
HZA-018 – Drug Profile
I-073 – Drug Profile
ianalumab – Drug Profile
IBL-202 – Drug Profile
ibrutinib – Drug Profile
IC-19/1563 – Drug Profile
ICP-248 – Drug Profile
IDP-121 – Drug Profile
IGM-8444 – Drug Profile
IKS-03 – Drug Profile
IMM-01 – Drug Profile
IMM-0306 – Drug Profile
immune globulin (human) – Drug Profile
IMN-003A – Drug Profile
imvotamab – Drug Profile
iodine i 131 apamistamab – Drug Profile
iopofosine i-131 – Drug Profile
IOV-2001 – Drug Profile
ipilimumab – Drug Profile
iPSC CAR-NK CD5 – Drug Profile
isatuximab – Drug Profile
IT-901 – Drug Profile
itacitinib adipate – Drug Profile
ixazomib citrate – Drug Profile
JBH-492 – Drug Profile
JCAR-014 – Drug Profile
JCAR-024 – Drug Profile
JD-001 – Drug Profile
JMT-601 – Drug Profile
JNJ-4681 – Drug Profile
JNJ-6633 – Drug Profile
JNJ-80948543 – Drug Profile
JNJ-8780 – Drug Profile
JRF-106 – Drug Profile
KA-2237 – Drug Profile
KAN-0439834 – Drug Profile
KAN-0441571 – Drug Profile
knetinib – Drug Profile
KPG-818 – Drug Profile
KUR-502 – Drug Profile
LAVA-051 – Drug Profile
LCB-71 – Drug Profile
lenalidomide – Drug Profile
Leukothera – Drug Profile
LGB-321 – Drug Profile
lisocabtagene maraleucel – Drug Profile
LNF-1904 – Drug Profile
loncastuximab tesirine – Drug Profile
LP-002 – Drug Profile
LP-102 – Drug Profile
LP-108 – Drug Profile
LP-118 – Drug Profile
LTZ-301 – Drug Profile
luxeptinib – Drug Profile
maltotriose dendrimer – Drug Profile
MB-106 – Drug Profile
MBCART-191 – Drug Profile
MH-048 – Drug Profile
MIL-62 – Drug Profile
MIR28 Replacement for Oncology – Drug Profile
Monoclonal Antibody for Chronic Lymphocytic Leukemia (CLL) and Mantle Cell Lymphoma (MCL) – Drug Profile
Monoclonal Antibody to Inhibit CD52 for Oncology – Drug Profile
Monoclonal Antibody to Inhibit STIM1 for Chronic Lymphocytic Leukemia – Drug Profile
mosunetuzumab – Drug Profile
MS-553 – Drug Profile
MU-1630 – Drug Profile
navtemadlin – Drug Profile
NC-1 – Drug Profile
nemtabrutinib – Drug Profile
NEOPV-01 – Drug Profile
NI-1701 – Drug Profile
nivolumab – Drug Profile
NNV-003 – Drug Profile
NNV-009 – Drug Profile
nogapendekin alfa – Drug Profile
NovalGen-I – Drug Profile
NRX-0492 – Drug Profile
NVG-111 – Drug Profile
NX-2127 – Drug Profile
NX-5948 – Drug Profile
obecabtagene autoleucel – Drug Profile
obinutuzumab – Drug Profile
ocaratuzumab – Drug Profile
Oncoquest – Drug Profile
Onureg – Drug Profile
orelabrutinib – Drug Profile
OSU-2S – Drug Profile
OSUT-315 – Drug Profile
OT-82 – Drug Profile
paclitaxel + rituximab – Drug Profile
parsaclisib – Drug Profile
PBCAR-20A – Drug Profile
pCAR-19B – Drug Profile
PD1 Gene knock-down anti-CD19 CAR-T Cell Immunotherapy – Drug Profile
pembrolizumab – Drug Profile
pirtobrutinib – Drug Profile
plamotamab – Drug Profile
PLX-51107 – Drug Profile
PRGN-3007 – Drug Profile
PSB-202 – Drug Profile
pyrimethamine – Drug Profile
QLP-31907 – Drug Profile
RC-1 – Drug Profile
RD-125 – Drug Profile
Recombinant Protein for Oncology – Drug Profile
relatlimab – Drug Profile
relmacabtagene autoleucel – Drug Profile
REMD-372 – Drug Profile
REMD-378 – Drug Profile
ricolinostat – Drug Profile
rituximab – Drug Profile
rituximab biobetter – Drug Profile
rituximab biosimilar – Drug Profile
romidepsin – Drug Profile
ruxolitinib phosphate – Drug Profile
S-055746 – Drug Profile
SACD19-101 – Drug Profile
SC-276 – Drug Profile
SC-291 – Drug Profile
SDGR-3 – Drug Profile
SDT-102 – Drug Profile
selinexor – Drug Profile
SFA-005 – Drug Profile
SG-233 – Drug Profile
SG-242 – Drug Profile
SG-2501 – Drug Profile
SG-295 – Drug Profile
SH-748 – Drug Profile
Small Molecule 1 for Chronic Lymphocytic Leukemia – Drug Profile
Small Molecule for Chronic Lymphocytic Leukemia – Drug Profile
Small Molecules to Inhibit CD38 for Multiple Myeloma and Chronic Lymphocytic Leukemia – Drug Profile
Small Molecules to Inhibit PIK3CD for Acute Myelocytic Leukemia and Chronic Lymphocytic Leukemia – Drug Profile
sovleplenib – Drug Profile
SS-001 – Drug Profile
subasumstat – Drug Profile
SYHA-1811 – Drug Profile
SYHX-1903 – Drug Profile
tafasitamab – Drug Profile
TAK-007 – Drug Profile
TCB-002 – Drug Profile
tenalisib – Drug Profile
TGRX-814 – Drug Profile
tinostamustine – Drug Profile
tirabrutinib hydrochloride – Drug Profile
tislelizumab – Drug Profile
TL-895 – Drug Profile
TQB-3473 – Drug Profile
TQB-3525 – Drug Profile
TQB-3820 – Drug Profile
Triplex – Drug Profile
TRS-006 – Drug Profile
TT-01488 – Drug Profile
TTI-621 – Drug Profile
ublituximab + umbralisib tosylate – Drug Profile
UBX-303 – Drug Profile
umbralisib tosylate – Drug Profile
Vaccine for Chronic Lymphocytic Leukaemia and Solid Tumor – Drug Profile
vactosertib – Drug Profile
vemurafenib – Drug Profile
venetoclax – Drug Profile
VIP-924 – Drug Profile
voruciclib – Drug Profile
WXSH-0057 – Drug Profile
Xembify – Drug Profile
XL-114 – Drug Profile
XNW-1011 – Drug Profile
YTB-323 – Drug Profile
YY-20394 – Drug Profile
YZJ-3058 – Drug Profile
zamtocabtagene autoleucel – Drug Profile
zandelisib – Drug Profile
zanubrutinib – Drug Profile
zilovertamab – Drug Profile
zilovertamab vedotin – Drug Profile
zuberitamab – Drug Profile
ZX-101A – Drug Profile
ZXBT-1158 – Drug Profile
ZYL-001 – Drug Profile
Chronic Lymphocytic Leukemia (CLL) – Dormant Projects
Chronic Lymphocytic Leukemia (CLL) – Discontinued Products
Chronic Lymphocytic Leukemia (CLL) – Product Development Milestones
Featured News & Press Releases
Nov 11, 2022: LAVA Therapeutics to present on-mechanism pharmacodynamics data from the phase 1/2a clinical trial of LAVA-051 at the Society for Immunotherapy of Cancer (SITC) 2022 Annual Meeting
Oct 14, 2022: BeiGene: Voluntary announcement – Update regarding recent business developments
Oct 12, 2022: BeiGene announces positive topline results from final progression-free survival analysis of BRUKINSA (zanubrutinib) compared to IMBRUVICA (ibrutinib) in Phase 3 Chronic Lymphocytic Leukemia (CLL) Trial
Sep 29, 2022: The Oncology Institute enrolls nation’s first two patients in a phase 3 open-label, randomized clinical trial of pirtobrutinib
Sep 06, 2022: China NMPA grants priority review for InnoCare’s orelabrutinib for lymphoma
Aug 09, 2022: Fate Therapeutics announces preclinical publication highlighting derivation of CD8aß T cells from TCR-CAR+ induced pluripotent stem cells
Aug 05, 2022: Calquence tablet formulation approved in the US across current indications
Aug 04, 2022: European Commission approves IMBRUVICA (ibrutinib) in a fixed-duration combination regimen for adult patients with previously untreated chronic lymphocytic leukaemia (CLL)
Jul 18, 2022: MEI Pharma and Kyowa Kirin announce publication in The Lancet Oncology of Data from phase 1b clinical study of zandelisib in patients with relapsed or refractory b-cell malignancy
Jul 15, 2022: EMA recommends extension of therapeutic indications for ibrutinib
Jun 24, 2022: Janssen receives positive CHMP opinion for IMBRUVICA (ibrutinib) in a fixed-duration combination regimen for adult patients with previously untreated chronic lymphocytic leukaemia (CLL)
Jun 16, 2022: LAVA Therapeutics highlights encouraging clinical updates on lead program, LAVA-051, in chronic lymphocytic leukemia and multiple myeloma patients
Jun 13, 2022: BeiGene announces PDUFA Goal date extension for U.S. sNDA for BRUKINSA for the Treatment of CLL/SLL
Jun 12, 2022: BeiGene highlights growing portfolio and pipeline targeting on BGB-11417 hematologic malignancies at European Hematology Association 2022 Congress
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Table 1: Number of Products under Development for Chronic Lymphocytic Leukemia (CLL), 2022
Table 2: Number of Products under Development by Companies, 2022
Table 3: Number of Products under Development by Companies, 2022 (Contd..1)
Table 4: Number of Products under Development by Companies, 2022 (Contd..2)
Table 5: Number of Products under Development by Companies, 2022 (Contd..3)
Table 6: Number of Products under Development by Companies, 2022 (Contd..4)
Table 7: Number of Products under Development by Companies, 2022 (Contd..5)
Table 8: Number of Products under Development by Companies, 2022 (Contd..6)
Table 9: Number of Products under Development by Companies, 2022 (Contd..7)
Table 10: Number of Products under Development by Companies, 2022 (Contd..8)
Table 11: Number of Products under Development by Companies, 2022 (Contd..9)
Table 12: Number of Products under Development by Companies, 2022 (Contd..10)
Table 13: Number of Products under Development by Companies, 2022 (Contd..11)
Table 14: Number of Products under Development by Universities/Institutes, 2022
Table 15: Number of Products under Development by Universities/Institutes, 2022 (Contd..1)
Table 16: Products under Development by Companies, 2022
Table 17: Products under Development by Companies, 2022 (Contd..1)
Table 18: Products under Development by Companies, 2022 (Contd..2)
Table 19: Products under Development by Companies, 2022 (Contd..3)
Table 20: Products under Development by Companies, 2022 (Contd..4)
Table 21: Products under Development by Companies, 2022 (Contd..5)
Table 22: Products under Development by Companies, 2022 (Contd..6)
Table 23: Products under Development by Companies, 2022 (Contd..7)
Table 24: Products under Development by Companies, 2022 (Contd..8)
Table 25: Products under Development by Companies, 2022 (Contd..9)
Table 26: Products under Development by Companies, 2022 (Contd..10)
Table 27: Products under Development by Companies, 2022 (Contd..11)
Table 28: Products under Development by Companies, 2022 (Contd..12)
Table 29: Products under Development by Companies, 2022 (Contd..13)
Table 30: Products under Development by Companies, 2022 (Contd..14)
Table 31: Products under Development by Companies, 2022 (Contd..15)
Table 32: Products under Development by Companies, 2022 (Contd..16)
Table 33: Products under Development by Companies, 2022 (Contd..17)
Table 34: Products under Development by Companies, 2022 (Contd..18)
Table 35: Products under Development by Companies, 2022 (Contd..19)
Table 36: Products under Development by Companies, 2022 (Contd..20)
Table 37: Products under Development by Companies, 2022 (Contd..21)
Table 38: Products under Development by Companies, 2022 (Contd..22)
Table 39: Products under Development by Companies, 2022 (Contd..23)
Table 40: Products under Development by Companies, 2022 (Contd..24)
Table 41: Products under Development by Companies, 2022 (Contd..25)
Table 42: Products under Development by Companies, 2022 (Contd..26)
Table 43: Products under Development by Universities/Institutes, 2022
Table 44: Products under Development by Universities/Institutes, 2022 (Contd..1)
Table 45: Products under Development by Universities/Institutes, 2022 (Contd..2)
Table 46: Number of Products by Stage and Target, 2022
Table 47: Number of Products by Stage and Target, 2022 (Contd..1)
Table 48: Number of Products by Stage and Target, 2022 (Contd..2)
Table 49: Number of Products by Stage and Target, 2022 (Contd..3)
Table 50: Number of Products by Stage and Target, 2022 (Contd..4)
Table 51: Number of Products by Stage and Target, 2022 (Contd..5)
Table 52: Number of Products by Stage and Mechanism of Action, 2022
Table 53: Number of Products by Stage and Mechanism of Action, 2022 (Contd..1)
Table 54: Number of Products by Stage and Mechanism of Action, 2022 (Contd..2)
Table 55: Number of Products by Stage and Mechanism of Action, 2022 (Contd..3)
Table 56: Number of Products by Stage and Mechanism of Action, 2022 (Contd..4)
Table 57: Number of Products by Stage and Mechanism of Action, 2022 (Contd..5)
Table 58: Number of Products by Stage and Route of Administration, 2022
Table 59: Number of Products by Stage and Molecule Type, 2022
Table 60: Chronic Lymphocytic Leukemia (CLL) – Pipeline by AbbVie Inc, 2022
Table 61: Chronic Lymphocytic Leukemia (CLL) – Pipeline by ABL Bio Inc, 2022
Table 62: Chronic Lymphocytic Leukemia (CLL) – Pipeline by Acerta Pharma BV, 2022
Table 63: Chronic Lymphocytic Leukemia (CLL) – Pipeline by Achelois Cell Therapy, 2022
Table 64: Chronic Lymphocytic Leukemia (CLL) – Pipeline by Actinium Pharmaceuticals Inc, 2022
Table 65: Chronic Lymphocytic Leukemia (CLL) – Pipeline by Actinobac Biomed Inc, 2022
Table 66: Chronic Lymphocytic Leukemia (CLL) – Pipeline by ADC Therapeutics SA, 2022
Table 67: Chronic Lymphocytic Leukemia (CLL) – Pipeline by Adlai Nortye Biopharma Co Ltd, 2022
Table 68: Chronic Lymphocytic Leukemia (CLL) – Pipeline by Advenchen Laboratories LLC, 2022
Table 69: Chronic Lymphocytic Leukemia (CLL) – Pipeline by AI Therapeutics Inc, 2022
Table 70: Chronic Lymphocytic Leukemia (CLL) – Pipeline by Alaunos Therapeutics Inc, 2022
Table 71: Chronic Lymphocytic Leukemia (CLL) – Pipeline by Alloplex Biotherapeutics Inc, 2022
Table 72: Chronic Lymphocytic Leukemia (CLL) – Pipeline by Amgen Inc, 2022
Table 73: Chronic Lymphocytic Leukemia (CLL) – Pipeline by Apotex Inc, 2022
Table 74: Chronic Lymphocytic Leukemia (CLL) – Pipeline by Ardan Pharma, 2022
Table 75: Chronic Lymphocytic Leukemia (CLL) – Pipeline by Ascenta Therapeutics Inc, 2022
Table 76: Chronic Lymphocytic Leukemia (CLL) – Pipeline by Ascentage Pharma Group International, 2022
Table 77: Chronic Lymphocytic Leukemia (CLL) – Pipeline by Astellas Pharma Inc, 2022
Table 78: Chronic Lymphocytic Leukemia (CLL) – Pipeline by AstraZeneca Plc, 2022
Table 79: Chronic Lymphocytic Leukemia (CLL) – Pipeline by Athenex Inc, 2022
Table 80: Chronic Lymphocytic Leukemia (CLL) – Pipeline by Aucentra Therapeutics Pty Ltd, 2022
Table 81: Chronic Lymphocytic Leukemia (CLL) – Pipeline by Autolus Therapeutics Plc, 2022
Table 82: Chronic Lymphocytic Leukemia (CLL) – Pipeline by Avesthagen Ltd, 2022
Table 83: Chronic Lymphocytic Leukemia (CLL) – Pipeline by AVM Biotechnology LLC, 2022
Table 84: Chronic Lymphocytic Leukemia (CLL) – Pipeline by BAKX Therapeutics Inc, 2022
Table 85: Chronic Lymphocytic Leukemia (CLL) – Pipeline by Bantam Pharmaceutical LLC, 2022
Table 86: Chronic Lymphocytic Leukemia (CLL) – Pipeline by Bayer AG, 2022
Table 87: Chronic Lymphocytic Leukemia (CLL) – Pipeline by BeiGene Ltd, 2022
Table 88: Chronic Lymphocytic Leukemia (CLL) – Pipeline by Beijing Gaobo Biotechnology Co Ltd, 2022
Table 89: Chronic Lymphocytic Leukemia (CLL) – Pipeline by Beijing GD Initiative Cell Therapy Technology Co Ltd, 2022
Table 90: Chronic Lymphocytic Leukemia (CLL) – Pipeline by Beijing Jingda Biotechnology Co Ltd, 2022
Table 91: Chronic Lymphocytic Leukemia (CLL) – Pipeline by Beijing Mabworks Biotech Co Ltd, 2022
Table 92: Chronic Lymphocytic Leukemia (CLL) – Pipeline by Bio-Path Holdings Inc, 2022
Table 93: Chronic Lymphocytic Leukemia (CLL) – Pipeline by Biocure Technology Inc, 2022
Table 94: Chronic Lymphocytic Leukemia (CLL) – Pipeline by Biogen Inc, 2022
Table 95: Chronic Lymphocytic Leukemia (CLL) – Pipeline by BioIntegrator, 2022
Table 96: Chronic Lymphocytic Leukemia (CLL) – Pipeline by Biomea Fusion Inc, 2022
Table 97: Chronic Lymphocytic Leukemia (CLL) – Pipeline by Bionomics Ltd, 2022
Table 98: Chronic Lymphocytic Leukemia (CLL) – Pipeline by BioNTech SE, 2022
Table 99: Chronic Lymphocytic Leukemia (CLL) – Pipeline by B

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings